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Fecal incontinence is a major public health issue that has yet to be adequately addressed. 
Obstetric trauma and injury to the anal sphincter muscles are the most common cause 
of fecal incontinence. New therapies are emerging aimed at repair or regeneration of 
sphincter muscle and restoration of continence. While regenerative medicine offers 
an attractive option for fecal incontinence there are currently no validated techniques 
using this approach. Although many challenges are yet to be resolved, the advent of 
regenerative medicine is likely to offer disruptive technologies to treat and possibly 
prevent the onset of this devastating condition. This article provides a review on 
regenerative medicine approaches for treating fecal incontinence and a critique of 
the current landscape in this area.
Keywords:  biomaterials • cell therapy • fecal incontinence • muscle • obstetric trauma 
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Pelvic floor maintenance of 
continence
Fecal incontinence (FI) is defined as invol-
untary loss of fecal material [1]. The anal 
sphincter consists of two muscular compo-
nents. The internal anal sphincter (IAS), 
which composed of a torus of smooth 
muscle, measures 0.3–0.5 cm in thickness 
and extends approximately 2.5 cm along 
the anal canal. The IAS is surrounded by 
the external anal sphincter (EAS), which 
is composed of skeletal muscle, and mea-
sures 0.6–1.0 cm in thickness and 8–10 cm 
in length (Figure 1) [2–4]. The two muscles 
contribute to approximately 70 and 30% of 
the basal resting tone, respectively, work-
ing in co-ordination to provide voluntary 
and involuntary control of continence and 
facilitate controlled closure of the anal canal 
[4,5]. The EAS is slow-twitch, type I striated 
muscle under voluntary control of sensory 
pudendal nerves in the anal canal and is not 
innervated by the enteric nervous system. 
Few other skeletal muscle structures in the 
human body share the circular layout with-
out tendons or direct connection to bone, 
while also generating tone at rest. The IAS 
is a ring of involuntary smooth muscle, con-
trolled by the autonomic nervous system 
providing tonic contraction [6]. Through 
tonic contraction, the IAS is principally 
responsible for anal continence at rest, 
whereas the EAS increases anal pressure in 
response to increased intra-rectal or intra-
abdominal pressure. Impairment of anal 
sphincter function leads to reduced resting 
pressure and is a cause of FI [7]. Additionally, 
the levator ani muscle which constitutes the 
pelvic floor, and puboretalis muscle, func-
tion as a sling to support the anorectal angle 
and contribute to continence [8]. Anal canal 
cushions are highly vascularized and inter-
digitated structures that provide a thick-
ened lining and have been postulated to 
contribute to the resting pressure [9]. How-
ever, this view is not accepted universally 
and studies have found no difference to 
continence despite removal of anal cushions 
posthemorrhoidectomy [10,11].
Defecation is controlled by coordinated 
sensory–motor innervation that uses nerves 
and muscles of the pelvic floor, EAS and 
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IAS. When the rectal threshold volume is reached, 
stretch receptors are activated in the myenteric plexus 
in the rectal walls along the pelvic floor, initiating 
a sensation of urge. Defecation reflexes, in the form 
of peristaltic waves in the descending colon and rec-
tum, force feces to the anus. Peristaltic waves towards 
the anus result in inhibitory signals from the myen-
teric plexus to cause the IAS to relax. If the EAS is 
also voluntarily relaxed at the same time, defeca-
tion occurs [12]. FI occurs when one or more of these 
mechanisms are disrupted and other mechanisms fail 
to compensate.
Current treatment
Treatment for FI varies with etiology. In the case of 
an obstetric injury, management of FI ranges from 
holistic approaches based on nutrition and psycho-
logical health, to surgery (Table 1). However, delayed 
and under-reporting of symptoms by patients in addi-
tion to a huge disparity in long-term monitoring of 
obstetric tears across the maternity care units makes 
this a challenging problem to tackle. Moreover, a 
UK-based study reported that almost two-thirds 
of clinicians practicing obstetrics felt inadequately 
trained in the training and management of obstetric 
trauma-induced anal sphincter injuries [13].
Obstetric trauma-induced FI
Obstetric trauma is a well-recognized cause of FI in 
women [14]. The prevalence of post partum FI reported 
in literature has a wide range varying from 3 to 29% 
[14–16]. Obstetric trauma-induced FI is attributed to 
two main causes: injury to pudendal nerve, which 
supplies the EAS and pelvic floor muscles [17], or to 
the anal sphincter muscles (EAS, IAS or both). Anal 
sphincters, being more amenable to treatment com-
pared with the pudendal nerve, have been the main 
focus of management therapies directed towards con-
trolling post partum FI. Although damage to the anal 
sphincter complex is common during vaginal delivery, 
it remains clinically undetected in 12–35% of patients 
[18]. Studies have revealed that a significant proportion 
of women with third- or fourth-degree tears become 
incontinent. A systematic review by Dudding et al. 
stated that up to two-thirds of women who sustain a 
recognized third-degree tear during delivery subse-
quently suffer with FI decades after childbirth [18,19]. 
There is a clear and unmet need for new approaches 
in the management and treatment of FI, which has 
been limited due to under-reporting and inaccurate 
demographics of FI.
This review focuses on regenerative medicine 
approaches for restoring the physiological function of 
sphincter muscle that is of potential clinical value. The 
review also aims to provide a critique of the current 
landscape for regenerative medicine being applied to 
obstetric trauma-induced FI.
Regenerative medicine
Regenerative medicine aims to restore functional tissue 
that is impaired due to aging, disease or injury. This 
promising field holds the potential for regeneration of 
impaired tissues by stimulating healing of the dam-
aged tissue or by allowing growth of tissues and organs 
in the laboratory, which can then be implanted into 
the body. The common approaches in this field include 
using cell therapy, biomaterials, a combination of both, 
or tissue engineering (TE).
Cell therapy involves the introduction of cells into 
a tissue with the aim of restoring lost tissue function. 
Table 1. Current treatment options available for fecal incontinence.
Noninvasive Minimally invasive Invasive
Lifestyle modification Biofeedback Anal sphincter repair
Dietary changes Bulking agents Artificial anal sphincters
Drugs Injectable microspheres Stoma
Pelvic floor exercises Cell therapy  
 Secca® (radiofrequency ablation)  
 Neuromodulation  
Figure 1. Anorectal anatomy. 
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Transplanted cells can modulate the host’s reparative 
response or may regenerate into new tissue itself. How-
ever, in cases of large tissue loss cell therapy alone is 
often not sufficient and there is a need for biomateri-
als to provide a provisional scaffold structure that can 
protect the cells during delivery and increase the like-
lihood of engraftment to form functional tissue. Bio-
materials do not only facilitate targeted cell delivery 
and integration with host tissue, but can also guide the 
healing process. Another promising approach is TE, 
which involves growth of functional organs in vitro 
that are subsequently implanted into the body. This 
technique utilizes three basic tools: cells, scaffolds and 
growth stimulatory signals (which maybe chemical 
or physical in nature). TE has received a lot of atten-
tion as an ideal treatment for many conditions, but it 
largely remains at the research stage.
Regenerative medicine offers an ideal solution for 
sphincter muscle damage caused by obstetric trauma 
where there is no associated neurological damage. It is 
feasible that many of these techniques, discussed in the 
ensuing sections, might be suitable for managing FI 
secondary to obstetric anal sphincter trauma.
Smart biomaterials
Basic TE principles rely on the use of biologically 
compatible material to deliver or initiate regeneration 
of tissue. Smart biomaterial scaffolds are made from 
a variety of materials to form 3D structures that can 
also be used to provide bioactive cues for cells for pro-
cesses such as facilitation of adhesion, proliferation and 
differentiation of cells. Bioactive scaffolds are designed 
to release chemical signals, such as chemokines and 
growth factors, into the surrounding environment. The 
3D structures can be designed to have specific degrada-
tion rates, pore size, porosity and surface topographies 
for optimal cell and tissue interaction. Material surface 
topography has been found to have a direct influence 
on the attachment and phenotype of cells to biomateri-
als. For example, studies with osteoblasts have shown 
they can be directed towards a proliferative phenotype 
when grown on a smooth surface compared with cells 
grown on a rough surface [20].
Injectable scaffolds are increasingly popular due to 
their macroscopic 3D properties for tissue regrowth 
and a microscopic framework to provide localized cell 
growth and tissue integration [21]. Appropriate poly-
mer selection and fabrication method of the scaffold 
is important to mimic endogenous tissue physiology 
or encourage extracellular matrix deposition for clini-
cal applications in translational research. The differ-
ent type of polymers along with their advantages and 
drawbacks are summarized in Table 2.
Natural polymers such as collagen-I and fibrin have 
been investigated for skeletal muscle regeneration. 
Collagen-I has been preferentially selected as a suit-
able biomaterial for applications such as striated muscle 
regeneration due to it being a predominant constituent 
of the extracellular matrix in natural skeletal muscle tis-
sue, hence its contribution to myoblast cell proliferation 
and differentiation. A main advantage is its elasticity 
during muscle contraction, which closely matches the 
physiological properties in skeletal muscle [22]. However, 
rapid shrinkage of pure collagen gels in vitro and poor 
stability in vivo limits their application [23]. Collagen 
sponges and hydrogels have been investigated for their 
ability to regenerate functional tissue [24,25]. A study by 
Beier et al. in which myoblast cells were attached to elec-
trospun pure collagen-I demonstrated high myoblast 
proliferation rate in a controlled orientation [26].
Fibrin is another material that has been explored for 
constructing matrices. Increased amounts of growth 
factors, such as VEGF, IGF1 and cytokine IL-1 are 
found in the presence of fibrin [27]. Upregulation of 
these signaling molecules may encourage host tissue 
remodeling and repair in the presence of fibrin. How-
Table 2. Examples of different types of polymer biomaterials and their advantages or 
disadvantages.
Type Advantage Disadvantage
Natural polymers Biocompatible Poor stability in vitro
Collagen Bioresorbable Rapid shrinkage
Fibrin Low immunogenicity Migration from implantation site
Synthetic polymers Improved stability in vivo compared with 
natural polymers
Elicit a greater immunogenic 
response compared with natural 
polymers
Poly-(lactic acid); poly-
(glycolic acid); poly-(lactic-
co-glycolic acid)
Poly-(lactic acid), poly-(glycolic acid), 
poly-(lactic-co-glycolic acid) – controllable 
degradation rates both in vitro and in vivo 
compared with natural polymers  
–
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ever, fibrin has shown poor stability in vitro beyond 
4 weeks, which may not permit comprehensive skeletal 
muscle regeneration in obstetric trauma patients with a 
third of fourth degree tear [28–30].
Synthetic biomaterials such as poly-(lactic acid) 
(PLA), poly-(glycolic acid) (PGA), and their copo-
lymer poly-(lactatic-co-glycolic acid) (PLGA) have 
improved stability and degradation rates both in vitro 
and in vivo compared with many natural polymers. 
Synthetic polymer scaffolds can be made with optimal 
features such as mechanical integrity to support tis-
sue ingrowth, high porosity to promote nutrient and 
gas exchange, controlled degradation, and release of 
bioactive agents over predetermined lengths of time.
A localized increase of growth factors at the site of 
injury may promote vascularization and regeneration 
of skeletal muscle tissue. However, bioactive factors 
to promote angiogenesis and tissue growth alone may 
be insufficient to promote full tissue restoration of the 
EAS muscle. The use of smart biomaterials in conjunc-
tion with cell delivery or engineered tissue construct 
implantation could improve neovascularization and 
enhance engraftment of delivered cells or tissue. Vascu-
larization is thought to be instrumental to the survival 
of tissue engineered constructs since gaseous exchange 
and nutrient diffusion in tissues are restricted to dis-
tances of no more than 200 μm. The lack of a vas-
cular network may result in cells at the center of the 
engineered tissue becoming hypoxic, which may lead 
to a necrotic core and loss of functional tissue. Encap-
sulation of anti-scarring agents, for example, isoforms 
of TGFβ within biomaterials to be delivered with 
cells or tissue may promote host tissue engraftment of 
implanted tissue for improved function [31].
Cell therapy
Many of the proposed regenerative medicine approaches 
for FI have been inspired by recent advances made in 
therapies for urinary incontinence and adapted for 
application to the anal sphincter. Autologous muscle 
progenitor cells have been shown to actively regenerate 
injured striated muscle of the urethral sphincter in rats. 
Injury was induced using electrocoagulation and uro-
dynamic testing results confirmed that 41% of sphinc-
ter function was restored within 1 month of muscle cell 
implantation [32]. Histology revealed replacement of 
mature myofibers, as well as restoration of innervated 
units in the regenerated sphincter muscle. This study 
demonstrates the feasibility of minimally invasive 
delivery of muscle progenitor cells to striated sphincter 
muscle with discrete injury. The use of electrocoagula-
tion to simulate obstetric injury irreversibly destroyed 
host myofibers and satellite cell activation. This type of 
injury is not entirely representative of obstetric injury, 
with irreversible myofiber destruction possibly limit-
ing the capacity of the delivered cells to engraft and 
facilitate host tissue. Furthermore, cell delivery at 37 
days postinjury was not conducted under guidance, 
thus introducing the possibility of cell misplacement 
and variability between recipients. To our knowledge, 
five US FDA-approved autologous cell therapy clinical 
trials targeting urinary incontinence have been per-
formed to date. These have shown encouraging results 
and are summarized in Table 3.
The first reported cell therapy clinical study for FI 
was performed by Frudinger et al. Autologous myo-
blasts were injected into the EAS of women with FI 
caused by obstetric trauma. Symptom duration ranged 
from 1 to 30 years in these patients prior to myo-
blast delivery. At 12 months follow-up there was an 
improvement in Wexner score that had decreased by a 
mean of 13.7 units and overall quality of life scores had 
improved by a median of 30 points. Although there was 
a significant increase in anal squeeze pressure at 1 and 
6 month, it was not sustained at 12 months postin-
jection [34]. This might suggest that the delivered cells 
provided little or no regeneration of the scarred anal 
sphincter muscle. The cause of this is unknown, but 
could be related to inefficient delivery and engraftment 
of viable cells into the host tissue. In vitro expansion of 
cells in 2D culture may impact on their behavior when 
delivered in vivo. The cells must first be detached and 
placed into a suspension before delivery to the muscle 
as an injected bolus. Without sufficient vasculariza-
tion many of the cells are unlikely to survive [41]. Itescu 
et al. have shown successful engraftment of autologous 
skeletal myoblasts delivered into injured myocardium, 
but survival of the implanted cells may be affected by 
alteration to their immunogenicity due to prolonged 
ex vivo culture [42]. Hodgetts et al. showed that 90% 
of cultured myoblasts die within 1 h of intravenous 
transplantation into dystrophic mice. The mechanisms 
attributed to this were:
•	 Natural killer cells responding to immunogenic 
antigens on transplanted myoblasts altered by 2D 
cell culture conditions;
•	 ’Natural’ host antibodies, which activate 
complement via a classical pathway;
•	 Binding of donor antigen to host antigen-presenting 
cells to present donor antigens to T cells [42,43].
For cell therapy to succeed as a regenerative medi-
cine therapy for incontinence, survival of transplanted 
cells and limitation of immune response may need to 
be further optimized.
For urinary incontinence, preclinical cell therapy 
studies have indicated autologous stem cells can restore 
www.futuremedicine.com 835future science group
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leak point pressure in stress urinary incontinence in a 
rat model [44]. Cell therapy has also been investigated in 
preclinical animal models of FI. Lorenzi and colleagues 
explored the use of bone marrow-derived mesenchymal 
stem cells to improve repair of sphincter muscle injury 
in rat models. Cells were delivered using intrasphinc-
teric injections after full thickness internal and exter-
nal sphincterotomy and end-to-end repair surgery. The 
results were compared with a control group that under-
went end-to-end repair and a saline injection. Results 
showed new muscle fiber formation with improved con-
traction in the cell delivery group compared with the 
control group [35]. While this study appears promising 
for the use of cell therapy to treat sphincter muscle injury, 
consideration should be given to the inherent regenera-
tive capacity of the injured tissue in the model used, the 
ability to precisely target the sphincter muscle of rodents, 
and whether the effect can be scaled-up for human use. 
There is little doubt that further preclinical studies such 
as these are required, not only for improving our under-
standing of the biological mechanisms involved, but also 
to help fine tune this approach for future clinical use.
The concept of muscle cell therapy has traditionally 
been thought to involve stem cell differentiation into 
functional muscle to regenerate damaged or dysfunc-
tional tissue. However, it is now widely accepted that 
differentiation alone is insufficient to achieve this aim. It 
is estimated almost 1 trillion cells are required to replace 
damaged cardiomyocytes during cardiac failure [45]. 
When scaling this number of cells into a rat model of 
cardiac failure, 2 billion cells are required for full restora-
tion – on the assumption that 100% of the transplanted 
cells will engraft and differentiate [45]. This figure is 
much higher than the amount of cells used in the major-
ity of preclinical studies published to date. Another step 
change in the mind set of research in the field of cell ther-
apy has been recognition of the importance of paracrine 
trophic factor release from mesenchymal stromal cells in 
tissue regeneration. The mechanisms behind this involve 
neutrophil infiltration to site of repair, macrophage acti-
vation, satellite cell proliferation and fusion, and neu-
romuscular junction formation [46]. Further studies 
are required to understand the paracrine mechanisms 
underlying tissue regeneration with cell transplantation.
Cell-biomaterial therapy
Biomaterials have been used in conjunction with cell-
based therapies to provide the mechanical and biological 
properties of host tissue and their extracellular matrix. 
Biomaterials provide a 3D scaffold for cells to form new 
tissue. Ideal properties of biomaterials for soft-tissues 
such as the sphincter muscle complex include biocom-
patibility, biodegradation and no significant immune 
response that may lead to diminished integration and 
functionality of delivered cells or tissue. The deliv-
ery of cell-biomaterial combination therapy has been 
explored in several animal models and FDA-approved 
cell therapy clinical trials.
Autologous urine-derived stem cells (UDSCs) have 
been delivered in a collagen-I hydrogel to the urethral 
sphincter in mouse model [47]. The UDSCs were geneti-
cally modified to express VEGF and implanted with 
endothelial cells. This study demonstrated the potential 
to deliver cell–biomaterial combinations together with 
bioactive factors to regenerate skeletal muscle in a model 
of urinary incontinence. The study by Shi et al. tested 
the functional regeneration of the urethral sphincter 
using adipose-derived mesenchymal stem cells (ADSCs) 
and silk fibroin microspheres as a bulking agent. ADSCs 
were found to be superior to the silk fibroin microspheres 
and showed long-term improvement at 12 weeks in com-
parison to only a short-term improvement up to 4 weeks 
seen with the silk fibroin microspheres. The leak point 
pressure increased to 59.74 ± 7.88 cm H
2
O (p < 0.05) 
with ADSCs, but stayed low at 33.59 ± 9.52 cm H
2
O 
(p > 0.05) with silk fibroin microspheres. Similarly, the 
lumen size decreased significantly in ADSCs group, but 
not with the silk fibroin microsphere group at 12 weeks 
[36]. This approach may offer clinical value for defects 
associated with the rhabdosphincter, which measures 
0.4–3.7 mm and is structurally thinner than the EAS, 
which measures 0.6–1.0 cm [4,48]. The difference in 
muscle thickness may explain why nonporous scaffolds 
do not provide sufficient mechanical integrity to sup-
port regeneration of larger muscle defects, where neo-
vascularization is needed for nutrient diffusion and 
removal of waste products to avoid tissue necrosis in the 
newly formed tissue.
Recently Kang et al. published the first preclinical 
in vivo study using a bioengineering approach for FI. 
They injected myoblast cell-loaded polycaprolactone 
beads into a dog model after inducing anal sphincter 
injury (partial extraction of approximately 25% of the 
posterior IAS/EAS using electrocautery). This study 
failed to demonstrate any histological or functional 
improvement postinjection [37].
Tissue-engineered constructs
In cardiovascular biology, cells have been combined 
with collagen to construct bioengineered multilayered 
blood vessels that resemble human arteries and are capa-
ble of withstanding physiological pressures [49]. A simi-
lar approach has been applied to bioengineering small 
3D IAS structures that show possible clinical value as a 
transplantable tissue [50,51]. Studies have shown the small-
scale bioengineered IAS can be engineered using human 
IAS smooth muscle cells. Functional analysis indicated 
the IAS rings generate spontaneous basal tone, contrac-
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tion in response to acetylcholine and neovascularization 
upon implantation onto a subcutaneous pocket on the 
upper back of mice [38]. While this approach demon-
strates feasibility to vascularize the construct, the chosen 
site of implantation may not be representative of poten-
tial vascularization at the site of intended delivery. The 
use of RAG1-/- mice with no mature B or T lympho-
cytes present may also have contributed to no observed 
immune response to the implanted construct [52]. Suit-
able sources of donor smooth muscle cells appropriate 
for bioengineering the construct may prove to be a 
limitation for this approach if translated to humans in 
the future. Another limitation is the time required to 
produce the construct. This would involve isolation and 
expansion of smooth muscle cells followed by formation 
of the mature IAS structure. By this stage, the injury 
may have undergone repair and scarring at the implan-
tation site, which may impede engraftment and contrac-
tility of the engineered construct. While a TE approach 
is very promising, there are significant hurdles to over-
come before this can be translated as a viable option for 
either IAS or EAS regeneration.
Conclusion
Regenerative medicine holds significant potential to 
restore muscle function following obstetric injury. Fur-
ther studies are necessary to verify preclinical findings 
and to optimize this type of therapeutic approach. An 
increasing awareness by women of the causes of FI and 
their willingness to openly discuss this condition, together 
with the rapid pace of development in the field of regen-
erative medicine will yield significant improvements in 
the treatments available for restoring continence.
Future perspective
The development of regenerative medicine strategies for 
obstetric trauma-induced FI is fast developing. Preclinical 
and early-phase clinical research into regeneration of mus-
cle for volumetric muscle loss and urinary incontinence 
provide great insight to improving targeted, localized cell 
delivery and the subsequent behavior of implanted cells. 
There are a number of recently completed and ongoing 
clinical trials investigating cell therapy that have demon-
strated safety, tolerance and feasibility of cell delivery in 
humans (Table 3). Recently, the focus has shifted towards 
the use of cells in combination with biomaterials to 
improve the efficiency and direct delivery of cells to the 
site of injury in vivo. Although further research is needed 
to optimize the choice of biomaterial and to understand 
cell behavior following implantation, the outlook for cell-
based therapies for FI appears to be promising for this 
form of regenerative medicine. Progress of this treatment 
will undoubtedly be accelerated as other forms of cell 
therapy become mainstream.
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Executive summary
Pelvic floor maintenance of continence
•	 Levator ani muscle and anal sphincters help maintain the continence mechanism.
Obstetric trauma-induced fecal incontinence
•	 Obstetric trauma is a well-recognized cause of fecal incontinence in women.
•	 Anal sphincter damage remains clinically undetected in 12–35% of patients.
Regenerative medicine
•	 Smart biomaterials are being evaluated for their use as 3D scaffolds for tissue regrowth and localized 
regeneration.
•	 Autologous cell therapy has been tested in five US FDA-approved clinical trials for muscle regeneration in 
incontinence with encouraging results.
•	 Cell-biomaterial therapy is being preclinically evaluated for targeted, localized delivery of cell-attached 
scaffolds and seems to be the most promising approach.
•	 Tissue-engineering constructs are being developed for partial or complete replacement of defective muscle.
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